| Name | Title | Contact Details |
|---|---|---|
Eugene Reilly |
Vice President and Chief Medical Information Officer | Profile |
Teresa Grogan |
VP and Chief Information Security Officer | Profile |
Thomas Bartiromo |
Vice President and Chief Technology Officer | Profile |
Thomas Bartiromo |
Vice President and Chief Information Officer | Profile |
Jonathan Banks |
Interim VP and Chief Information Security Officer | Profile |
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Premier Lifts is a Lutherville Timonium, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MED e-care Healthcare Solutions Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedVentive provides leading-edge technology solutions that enable physician groups, integrated delivery systems, health plans and self-insured employers to effect meaningful and measurable change in the quality and cost of care they deliver to patients.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa, and Montreal.